Active substance
Recombinat dna coagulating factor vlla eptacog alfa activated
- SFDA 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NOVOSEVEN 1MG POWDER FOR SOLUTION FOR INJECTION | 1 mg | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 3168.00 | Biological · Prescription | NOVO NORDISK | Valid |
| NOVOSEVEN 2MG POWDER FOR SOLUTION FOR INJECTION | 2 mg | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 6348.50 | Biological · Prescription | NOVO NORDISK | Valid |
| NOVOSEVEN 5MG POWDER FOR SOLUTION FOR INJECTION | 5 mg | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 15842.65 | Biological · Prescription | NOVO NORDISK | Valid |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ MANAGEMENT OF BLEEDING; HEMOPHILIA A, HEMOPHILIA B, ACQUIRED HEMOPHILIA
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.